Business Summary

Shire is a holding company. The Company and its subsidiaries is a biopharmaceutical company that focuses on developing and marketing medicines that address unmet patient needs. The Company has four commercial units that focus on the commercial execution of its In-Line products in the following specialist therapeutic areas: rare diseases, neuroscience, gastrointestinal and internal medicine. The Company's main marketed products include VYVANSE/VENVANSE/ELVANSE/TYVENSE (lisdexamfetamine dimesylate) for the treatment of Attention Deficit Hyperactivity Disorder; LIALDA (mesalamine)/ MEZAVANT(mesalazine) for the treatment of ulcerative colitis; as well as REPLAGAL which is marketed for the treatment of Fabry disease.

Data provided by Mergent, Inc.

Recent Company News MORE »

Powered by Interactive Data Managed Solutions
DR Symbol SHPG
CUSIP 82481R106
DR Exchange NASDAQ Stock Market
DR ISIN US82481R1068
Ratio DR:ORD 1:3
Depositary CIT (Sponsored)
Effective Date May 12, 2011
Underlying ISIN JE00B2QKY057
Country United Kingdom
Industry Pharma. & Biotech.

Powered by Interactive Data Managed Solutions

Monthly DR Trading Summary MORE »

Month Month End
DR Close
DR Trading Volume Avg Day DR
Sep. 15 205.23 18,117,536 862,740
Aug. 15 232.00 19,750,771 940,513
Jul. 15 266.81 13,148,888 597,677
Data provided by Interactive Data Corp.

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to
"Terms Of Use".

Data provided by Thomson Reuters, Inc.

© 2015 The Bank of New York Mellon Corporation. Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Quotes delayed at least 15 minutes.Market data provided by Interactive Data
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Certain information included in this website is proprietary to Mergent, Inc. (Mergent) Copyright 2003-2010. Reproduction of such information in any form is prohibited. Because of the possibility of
human or mechanical error by Mergent's sources, Mergent or others, Mergent does not guarantee the accuracy, adequacy, completeness, timeliness or availability or for the results obtained from the
use of such information. Mergent Terms of Use apply

Holdings information provided by FactSet Research Systems Inc. Copyright 2003-2015 FactSet Research Systems Inc. All rights reserved.

Thomson Reuters Marks: The THOMSON REUTERS Kinesis Logo depicted below and THOMSON REUTERS

Redistributor shall display or print the Thomson Reuters Trademarks when Redistributor’s Customers are given access to the Services.

Where Redistributor makes available on display any and all Thomson Reuters Marks attributable to the Services, Redistributor shall include the following language in the Help About
section or in a general attribution page: “The THOMSON REUTERS Kinesis Logo and THOMSON REUTERS are trademarks of Thomson Reuters and its affiliated companies in the
United States and other countries and used herein under license.”

Additional Attribution Guidelines by Thomson Reuters: Redistributor shall display or print the following notice in the Help About section or in a general attribution page. “Copyright ©,
Thomson Reuters, 1999-2015. All Rights Reserved. Use, duplication, or sale of this service, or data contained herein, except as described in the [Authorized Products name]
Subscription Agreement, is strictly prohibited.”